🇺🇸 FDA
Patent

US 12290531

Compositions targeting BCMA and methods of use thereof

granted A61KA61K2039/505A61K2239/13

Quick answer

US patent 12290531 (Compositions targeting BCMA and methods of use thereof) held by Takeda Pharmaceutical Company Limited expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2239/13, A61K2239/21, A61K2239/25